Axa S.A. Vir Biotechnology, Inc. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $1.6 Million - $2.22 Million	-71,800 Reduced 88.42%	9,400 $218,000
Q4 2022 Feb 14, 2023	BUY	$19.96 - $28.22 $1.05 Million - $1.49 Million	52,700 Added 184.91%	81,200 $2.06 Million
Q3 2022 Feb 14, 2023	BUY	$18.26 - $31.1 $275,726 - $469,610	15,100 Added 112.69%	28,500 $549,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $520,410 - $886,350	28,500 New	28,500 $550,000
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $255,671 - $357,780	-13,400 Closed	0 $0
Q1 2022 Feb 14, 2023	SELL	$21.19 - $40.01 $319,969 - $604,151	-15,100 Reduced 52.98%	13,400 $344,000
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $283,946 - $536,134	13,400 New	13,400 $345,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $979M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.